However, with the advent of agents that inhibit the bioactivity of vascular endothelial growth factor (VEGF) and studies that test efficacy and safety of dose, it has been realized that anti-VEGF agents can change the natural history of ROP and that intravitreal neovascularization and later tractional retinal detachments occur even a year after an injection [25]. Here, VEGFA is linked to retinopathy of prematurity.